Effects of adenosine A2A receptor low affinity agonist Regadenoson in patients with obstructive pulmonary disease, at risk for adenosine-induced bronchoconstriction mediated via A2B and/or A3 adenosine receptors.
— · The Internet Journal of Cardiovascular Research · 2009
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
The Internet Journal of Cardiovascular Research · OpenAlex · article · 2009
Abstract
The pharmaceutical Regadenoson (Lexiscan TM ) Produced by Astellas Inc. Is currently in use as a pharmacological stress agent for myocardial perfusion imaging within the field of Nuclear Cardiology. Regadenoson is a selective A 2A adenosine receptor agonist, and also has a low affinity for adenosine receptors which cause bronchoconstriction in patients with reactive airways mediated via A 2B and A3 adenosine receptors. In a study of 42 patients with mild to moderate asthma and/or moderate to severe COPD who had a positive adenosine monophosphate test, Regadenoson proved to be relatively safe and well tolerated by most patients (90%).
8 Regadenoson is a low affinity agonist (Ki H 1.3 µM) for the A2A adenosine receptor, with at least 10-fold lower affinity for the A1 adenosine receptor (Ki > 16.5 µM), and weak, if any, affinity for the A2B and A3 adenosine receptors. 2,9 Activation of the A2A adenosine receptor by regadenoson produces coronary vasodilation 8 and increases coronary blood flow (CBF). It
Open the resolved locator · 10.5580/ff4
Metadata licence: OpenAlex metadata (CC0)